Scientists Identify Main Cause of Extreme Nausea and Vomiting in Pregnancy

Why It Matters

Identifying GDF15 as the primary driver opens a clear therapeutic target for a condition that currently lacks FDA‑approved treatments, potentially reducing hospitalizations and improving maternal health. The genetic overlap with type 2 diabetes also creates cross‑disease drug development opportunities.

Key Takeaways

• GDF15 gene identified as primary driver of hyperemesis gravidarum
• TCF7L2 links HG risk to type 2 diabetes susceptibility
• Metformin trial will test GDF15 desensitization before conception
• GDF15 signal confirmed across European, Asian, African, Latino groups
• No genetic ties found for hCG or estrogen in HG

Pulse Analysis

Hyperemesis gravidarum (HG) affects roughly one in ten pregnant individuals, often leading to severe dehydration, weight loss, and hospitalization. Despite its prevalence, the condition has no FDA‑approved therapies, leaving clinicians to manage symptoms with supportive care alone. The new multi‑ancestry genome‑wide association study, the largest of its kind, provides a breakthrough by isolating GDF15 as the most significant genetic contributor, shifting the focus from hormonal theories to a molecular pathway that can be targeted pharmacologically.

GDF15, a hormone released by the placenta and stressed cells, signals through the brainstem to suppress appetite and induce nausea. Its elevated levels in early pregnancy have long been observed, but this study confirms that specific GDF15 mutations can increase HG risk tenfold. Moreover, the identification of TCF7L2—a gene central to glucose regulation and the target of GLP‑1 agonists like Ozempic—creates a mechanistic bridge between HG and metabolic disorders such as type 2 diabetes. This convergence suggests that drugs modulating the GDF15‑GLP‑1 axis could address both nausea in pregnancy and broader metabolic health.

The clinical implications are immediate. A planned metformin trial aims to pre‑emptively blunt GDF15 signaling in women with prior HG, leveraging metformin’s known ability to raise circulating GDF15. Success could usher in the first disease‑modifying therapy for HG and stimulate pharmaceutical investment in GDF15 antagonists. Beyond treatment, the genetic markers identified may enable early risk stratification, allowing obstetricians to personalize monitoring and counseling. As the research expands to more diverse populations, the findings promise to reshape prenatal care, reduce costly hospital stays, and improve outcomes for millions of families worldwide.